Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer.

Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hortobagyi GN, Hayes DF, Ambrosone CB.

Breast Cancer Res Treat. 2010 Nov;124(2):433-9. doi: 10.1007/s10549-010-0840-0. Epub 2010 Mar 23.

2.

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.

Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Osborne CK; Breast Cancer Intergroup of North America.

Lancet. 2009 Dec 19;374(9707):2055-2063. doi: 10.1016/S0140-6736(09)61523-3. Epub 2009 Dec 10.

3.

Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.

Choi JY, Barlow WE, Albain KS, Hong CC, Blanco JG, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hayes DF, Ambrosone CB.

Clin Cancer Res. 2009 Aug 15;15(16):5258-66. doi: 10.1158/1078-0432.CCR-09-0685. Epub 2009 Aug 11.

4.

Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).

Davidson NE, O'Neill AM, Vukov AM, Osborne CK, Martino S, White DR, Abeloff MD.

J Clin Oncol. 2005 Sep 1;23(25):5973-82. Epub 2005 Aug 8.

PMID:
16087950
5.

Adjuvant chemotherapy for postmenopausal lymph node-negative breast cancer: it ain't necessarily so.

Wolff AC, Abeloff MD.

J Natl Cancer Inst. 2002 Jul 17;94(14):1041-3. No abstract available.

PMID:
12122089
6.

A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).

Gradishar WJ, Stephenson P, Glover DJ, Neuberg DS, Moore MR, Windschitl HE, Piel I, Abeloff MD.

Cancer. 2001 Nov 15;92(10):2517-22.

PMID:
11745184
7.

Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.

Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E.

J Natl Cancer Inst. 2001 Feb 21;93(4):309-14.

PMID:
11181778
8.

Adjuvant systemic management of early stage carcinoma of the breast.

Wolff AC, Abeloff MD.

Surg Oncol. 1999 Aug;8(2):93-101. Review.

PMID:
10732961
9.

Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185).

Kucuk O, Pandya KJ, Skeel RT, Hochster H, Abeloff MD.

Breast Cancer Res Treat. 1999 Sep;57(2):201-6.

PMID:
10598047
10.

International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury.

Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Philip T, Coiffier B.

J Clin Oncol. 1999 Jan;17(1):423-9. Review. No abstract available.

PMID:
10458261
11.

A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer.

Subramanyan S, Abeloff MD, Bond SE, Davidson NE, Fetting JH, Gordon GB, Kennedy MJ.

Cancer Chemother Pharmacol. 1999;43(6):497-502.

PMID:
10321510
12.

Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.

Mikhak B, Zahurak M, Abeloff MD, Fetting JH, Davidson NE, Donehower RC, Waterfield W, Kennedy MJ.

Cancer. 1999 Feb 15;85(4):899-904.

PMID:
10091768
13.

International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury.

Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Coiffier B, Philip T.

Ann Oncol. 1999 Jan;10(1):13-9. Review. No abstract available.

PMID:
10076716
14.

Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.

Fetting JH, Gray R, Fairclough DL, Smith TJ, Margolin KA, Citron ML, Grove-Conrad M, Cella D, Pandya K, Robert N, Henderson IC, Osborne CK, Abeloff MD.

J Clin Oncol. 1998 Jul;16(7):2382-91.

PMID:
9667255
15.

Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.

Falkson G, Gelman RS, Pandya KJ, Osborne CK, Tormey D, Cummings FJ, Sledge GW, Abeloff MD.

J Clin Oncol. 1998 May;16(5):1669-76.

PMID:
9586877
16.

Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.

Rivkin SE, Green S, O'Sullivan J, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Osborne CK.

J Clin Oncol. 1996 Jan;14(1):46-51.

PMID:
8558219
17.

Vinorelbine (Navelbine) in the treatment of breast cancer: a summary.

Abeloff MD.

Semin Oncol. 1995 Apr;22(2 Suppl 5):1-4; discussion 41-4.

PMID:
7740330
18.

Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup study.

Budd GT, Green S, O'Bryan RM, Martino S, Abeloff MD, Rinehart JJ, Hahn R, Harris J, Tormey D, O'Sullivan J, et al.

J Clin Oncol. 1995 Apr;13(4):831-9.

PMID:
7707108
19.

Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.

Rivkin SE, Green S, Metch B, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Minton JP, Osborne CK.

J Clin Oncol. 1994 Oct;12(10):2078-85.

PMID:
7931477
20.

Professionalism and cancer care.

Abeloff MD, Reynolds PP.

Bull Am Coll Surg. 1994 May;79(5):12-7. No abstract available.

PMID:
10134112
21.

Adjuvant therapy of breast cancer.

Davidson NE, Abeloff MD.

World J Surg. 1994 Jan-Feb;18(1):112-6.

PMID:
8197765
22.

Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer.

Osborne CK, Sunderland MC, Neidhart JA, Ravdin PM, Abeloff MD.

Ann Oncol. 1994 Jan;5(1):43-7.

PMID:
8172792
23.

Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer.

Armstrong DK, Fetting JH, Davidson NE, Gordon GB, Huelskamp AM, Abeloff MD.

Breast Cancer Res Treat. 1993 Dec;28(3):277-84.

PMID:
8018956
24.

Phase II study of goserelin for patients with postmenopausal metastatic breast cancer.

Saphner T, Troxel AB, Tormey DC, Neuberg D, Robert NJ, Pandya KJ, Edmonson JH, Rosenbluth RJ, Abeloff MD.

J Clin Oncol. 1993 Aug;11(8):1529-35.

PMID:
8336191
25.

Menstrual effects on surgical treatment for breast cancer.

Davidson NE, Abeloff MD.

Cancer Treat Rev. 1993 Apr;19(2):105-12. Review. No abstract available.

PMID:
8481925
26.

Management of locally recurrent breast cancer.

Kennedy MJ, Abeloff MD.

Cancer. 1993 Apr 1;71(7):2395-409. Review.

PMID:
8453561
27.

Maintenance tamoxifen after induction postoperative chemotherapy in node-positive breast cancer patients: the Eastern Cooperative Oncology Group Trials.

Tormey DC, Gray R, Falkson HC, Gilchrist K, Abeloff MD, Falkson G.

Recent Results Cancer Res. 1993;127:185-96. No abstract available.

PMID:
8502815
28.

High-dose adjuvant chemotherapy for high-risk breast cancer.

Abeloff MD.

Recent Results Cancer Res. 1993;127:177-83. Review. No abstract available.

PMID:
8502814
29.

Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial.

Tormey DC, Gray R, Abeloff MD, Roseman DL, Gilchrist KW, Barylak EJ, Stott P, Falkson G.

J Clin Oncol. 1992 Dec;10(12):1848-56.

PMID:
1453199
30.

Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study.

Ettinger DS, Finkelstein DM, Abeloff MD, Skeel RT, Stott PB, Frontiera MS, Bonomi PD.

J Natl Cancer Inst. 1992 Jul 15;84(14):1077-84.

PMID:
1320131
31.

Off-label uses of anticancer drugs.

Abeloff MD.

JAMA. 1992 May 13;267(18):2473-4. No abstract available.

PMID:
1573723
32.

Adjuvant systemic therapy in women with early-stage breast cancer at high risk for relapse.

Davidson NE, Abeloff MD.

J Natl Cancer Inst. 1992 Mar 4;84(5):301-5. No abstract available.

PMID:
1531367
33.

Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients.

Clark GM, Mathieu MC, Owens MA, Dressler LG, Eudey L, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff MD, et al.

J Clin Oncol. 1992 Mar;10(3):428-32.

PMID:
1740681
34.

Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076).

Dressler LG, Eudey L, Gray R, Tormey DC, McGuire WL, Gilchrist KW, Clark GM, Osborne CK, Mansour EG, Abeloff MD.

J Natl Cancer Inst Monogr. 1992;(11):167-72.

PMID:
1627424
35.

Adjuvant chemotherapy of axillary lymph-node-positive breast cancer.

Davidson NE, Abeloff MD.

Cancer Treat Res. 1992;60:115-45. Review. No abstract available.

PMID:
1355983
36.

Breast cancer.

Abeloff MD.

Curr Opin Oncol. 1991 Dec;3(6):985-7. No abstract available.

PMID:
1843116
37.

Burnout in oncology--physician heal thyself.

Abeloff MD.

J Clin Oncol. 1991 Oct;9(10):1721-2. No abstract available.

PMID:
1919621
38.

High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer.

Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Abeloff MD, Davidson NE.

J Natl Cancer Inst. 1991 Jul 3;83(13):920-6.

PMID:
1906111
39.

Effect of patients' expectations of benefit with standard breast cancer adjuvant chemotherapy on participation in a randomized clinical trial: a clinical vignette study.

Fetting JH, Siminoff LA, Piantadosi S, Abeloff MD, Damron DJ, Sarsfield AM.

J Clin Oncol. 1990 Sep;8(9):1476-82.

PMID:
2202790
40.

Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).

Noe DA, Rowinsky EK, Shen HS, Clarke BV, Grochow LB, McGuire WB, Hantel A, Adams DB, Abeloff MD, Ettinger DS, et al.

Cancer Res. 1990 Aug 1;50(15):4595-9.

41.

Phase II trial of menogaril as initial chemotherapy for metastatic breast cancer.

Kennedy MJ, Donehower RC, Grochow LB, Ettinger DS, Fetting JH, Abeloff MD.

Invest New Drugs. 1990 Aug;8(3):289-94.

PMID:
2148742
42.

Decreased erythropoietin response in patients with the anemia of cancer.

Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL.

N Engl J Med. 1990 Jun 14;322(24):1689-92.

43.

Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer.

Ettinger DS, Finkelstein DM, Abeloff MD, Chang YC, Smith TJ, Oken MM, Ruckdeschel JC.

Invest New Drugs. 1990 May;8(2):183-5.

PMID:
2166720
44.

Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer.

Abeloff MD, Beveridge RA, Donehower RC, Fetting JH, Davidson NE, Gordon GG, Waterfield WC, Damron DJ.

J Natl Cancer Inst. 1990 Apr 4;82(7):570-4.

PMID:
2313733
45.

High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease.

Jones RJ, Piantadosi S, Mann RB, Ambinder RF, Seifter EJ, Vriesendorp HM, Abeloff MD, Burns WH, May WS, Rowley SD, et al.

J Clin Oncol. 1990 Mar;8(3):527-37.

PMID:
2307990
46.

The clinical significance of variant-morphology small-cell carcinoma of the lung.

Aisner SC, Finkelstein DM, Ettinger DS, Abeloff MD, Ruckdeschel JC, Eggleston JC.

J Clin Oncol. 1990 Mar;8(3):402-8.

PMID:
2155311
48.

Carboplatin substitution for cisplatin in the treatment of ovarian carcinoma--a word of caution.

McGuire WP, Abeloff MD.

J Natl Cancer Inst. 1989 Oct 4;81(19):1438-9. No abstract available.

PMID:
2674458
49.

Doctor-patient communication about breast cancer adjuvant therapy.

Siminoff LA, Fetting JH, Abeloff MD.

J Clin Oncol. 1989 Sep;7(9):1192-200.

PMID:
2671280
50.

Treatment of stage III breast cancer. A panel discussion.

McGuire WL, Abeloff MD, Hortobagyi GN, Swain SM.

Breast Cancer Res Treat. 1989 Jul;13(3):225-35.

PMID:
2758112

Supplemental Content

Loading ...
Support Center